citalopram has been researched along with Anxiety Neuroses in 188 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17." | 9.41 | Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. ( Cecil, KM; DelBello, MP; Gong, Q; Huang, X; Li, H; Lu, L; Mills, JA; Mossman, SA; Ramsey, LB; Schroeder, HK; Strawn, JR; Sweeney, JA; Varney, ST, 2021) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 9.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders." | 9.14 | Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2010) |
| "In this 32-week study of citalopram for elderly persons with anxiety disorders, 60% responded." | 9.12 | Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. ( Blank, S; Dew, MA; Houck, PR; Karp, JF; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Shear, MK; Tracey, B, 2006) |
| "We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients." | 9.12 | Bupropion in the treatment of outpatients with asthma and major depressive disorder. ( Brown, ES; Khan, DA; Rush, AJ; Vornik, LA, 2007) |
| "The aim of this study was to examine the association between polymorphism in the serotonin transporter gene and citalopram effectiveness and side effects in children and adolescents with major depressive disorder (MDD) and/or anxiety disorders." | 9.12 | Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2007) |
| "To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders." | 9.11 | Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. ( Axelson, D; Birmaher, B; Brent, DA; Bridge, J; Campo, JV; Di Lorenzo, C; Ehmann, M; Kalas, C; Lucas, A; Monk, K; Perel, J; Ryan, N, 2004) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 8.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| "Escitalopram, the active (S)-enantiomer of citalopram, has been approved in many countries throughout the world for the treatment of depression and anxiety disorders." | 8.84 | The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. ( Altamura, AC; Bareggi, SR; Dell'Osso, B; Mundo, E, 2007) |
| "Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability." | 8.84 | Escitalopram therapy for major depression and anxiety disorders. ( Baldwin, DS; Guiton, C; Reines, EH; Weiller, E, 2007) |
| "The suicide-related data on citalopram from controlled clinical trials in depression and anxiety disorders were analysed." | 8.83 | Citalopram and suicidality in adult major depression and anxiety disorders. ( Pedersen, AG, 2006) |
| " The current investigation attempted to identify potential predictors of placebo response through examination of the placebo-controlled clinical trial database for escitalopram in 3 anxiety disorders and in major depressive disorder (MDD)." | 8.83 | Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. ( Baldwin, DS; Bandelow, B; Despiegel, N; Dolberg, OT; Stein, DJ, 2006) |
| "For the first time, this study analyzed how the DHPC affected the prescription of citalopram and escitalopram in patients with anxiety disorders." | 8.12 | [Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders]. ( Belz, M; Degner, D; Greil, W; Grohmann, R; Köberle, U, 2022) |
| "The study revealed that patients treated with escitalopram had a reduction of psycho-diagnostic test scores that measure depression and anxiety levels as well as the values of pruritus." | 7.80 | Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. ( Agnoletti, AF; Betti, S; Campolmi, E; Cossidente, A; D'Erme, AM; Lotti, T; Santosuosso, U; Zanieri, F, 2014) |
| "The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to citalopram among children and adolescents with depression and/or anxiety disorders." | 7.79 | Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Kronenberg, S; Rotberg, B; Weizman, A; Zalsman, G, 2013) |
| "Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed." | 7.71 | Citalopram for the treatment of adolescent anxiety disorders: a pilot study. ( Bostic, JQ; Brown, K; Monuteaux, M; Place, S; Prince, JB, 2002) |
| "Citalopram-treated subjects showed significantly greater improvement in reappraisal ability than CBT-waitlisted subjects." | 6.84 | Emotional Reactivity and Regulation Following Citalopram Therapy in Children and Adolescents with Anxiety Disorders. ( Apter, A; Benaroya-Milshtein, N; Carthy, T; Valevski, A, 2017) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 6.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose." | 6.43 | Managing depressive and anxiety disorders with escitalopram. ( Thase, ME, 2006) |
| "Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17." | 5.41 | Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial. ( Cecil, KM; DelBello, MP; Gong, Q; Huang, X; Li, H; Lu, L; Mills, JA; Mossman, SA; Ramsey, LB; Schroeder, HK; Strawn, JR; Sweeney, JA; Varney, ST, 2021) |
| "Citalopram treatment resulted in significant deactivation (p = 0." | 5.32 | Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. ( Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004) |
| "The objectives were to characterize latent depression subtypes by symptoms, evaluate sex differences in and examine correlates of these subtypes, and examine the association between subtype and symptom remission after citalopram treatment." | 5.20 | The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2015) |
| "To assess the effectiveness and tolerability of citalopram for the acute treatment of children and adolescents suffering from depression and/or anxiety disorders." | 5.14 | Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2010) |
| " While it is well known that SSRI are efficient in treating depression or anxiety disorders, the authors tried to determine the influence of baseline anxiety on the response to SSRI treatment in patients with severe depression receiving either escitalopram or paroxetine." | 5.14 | [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. ( Chauvet-Gélinier, JC, 2010) |
| "In this 32-week study of citalopram for elderly persons with anxiety disorders, 60% responded." | 5.12 | Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment. ( Blank, S; Dew, MA; Houck, PR; Karp, JF; Lenze, EJ; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Shear, MK; Tracey, B, 2006) |
| "The aim of this study was to examine the association between polymorphism in the serotonin transporter gene and citalopram effectiveness and side effects in children and adolescents with major depressive disorder (MDD) and/or anxiety disorders." | 5.12 | Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Gothelf, D; Kronenberg, S; Melhem, N; Pick, N; Schirman, S; Weizman, A, 2007) |
| "We conducted a 12-week open-label study of bupropion in 18 depressed asthma patients." | 5.12 | Bupropion in the treatment of outpatients with asthma and major depressive disorder. ( Brown, ES; Khan, DA; Rush, AJ; Vornik, LA, 2007) |
| "To assess the potential efficacy, tolerability, and safety of citalopram in the treatment of functional pediatric recurrent abdominal pain and comorbid internalizing disorders." | 5.11 | Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. ( Axelson, D; Birmaher, B; Brent, DA; Bridge, J; Campo, JV; Di Lorenzo, C; Ehmann, M; Kalas, C; Lucas, A; Monk, K; Perel, J; Ryan, N, 2004) |
| " They also suggest that lithium for comorbid bipolar disorder, escitalopram for comorbid anxiety disorders, and the addition of CBT to standard drug treatment for comorbid schizophrenia may be effective." | 4.93 | Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research. ( Dowling, NA; Lorains, FK; Merkouris, SS, 2016) |
| "Escitalopram, the active (S)-enantiomer of citalopram, has been approved in many countries throughout the world for the treatment of depression and anxiety disorders." | 4.84 | The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. ( Altamura, AC; Bareggi, SR; Dell'Osso, B; Mundo, E, 2007) |
| "Randomized controlled clinical trials have demonstrated that escitalopram is efficacious in a range of mood and anxiety disorders, but the individual trials are insufficiently large to allow a full exploration of its tolerability." | 4.84 | Escitalopram therapy for major depression and anxiety disorders. ( Baldwin, DS; Guiton, C; Reines, EH; Weiller, E, 2007) |
| "This review focuses on the therapeutic use and the tolerability issues of escitalopram in the treatment of adult patients with panic disorder, generalized anxiety disorder (GAD), social anxiety disorder, and obsessive-compulsive disorder (OCD), on the basis of numerous recent short-term and long-term controlled studies in these disorders." | 4.84 | [Efficacy and tolerability of escitalopram in anxiety disorders: a review]. ( Pelissolo, A, 2008) |
| " The current investigation attempted to identify potential predictors of placebo response through examination of the placebo-controlled clinical trial database for escitalopram in 3 anxiety disorders and in major depressive disorder (MDD)." | 4.83 | Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram. ( Baldwin, DS; Bandelow, B; Despiegel, N; Dolberg, OT; Stein, DJ, 2006) |
| "The suicide-related data on citalopram from controlled clinical trials in depression and anxiety disorders were analysed." | 4.83 | Citalopram and suicidality in adult major depression and anxiety disorders. ( Pedersen, AG, 2006) |
| " We sought to determine these thresholds by comparing, in a post hoc analysis, scores on the Clinical Global Impressions scale (CGI) and disorder-specific symptom severity rating scales from all available studies of the treatment of major depressive disorder, panic disorder, generalized anxiety disorder, and social anxiety disorder with the same medication (escitalopram)." | 4.83 | What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder? ( Andersen, HF; Baldwin, DS; Bandelow, B; Dolberg, OT; Stein, DJ, 2006) |
| "The escitalopram clinical trial database, consisting of all placebo-controlled and relapse prevention trials within major depressive disorder (MDD) and anxiety disorders, was analysed for specific adverse events indicative of suicidal behaviour (fatal suicide, non-fatal self-harm or suicidal thoughts) in relation to treatment." | 4.82 | Escitalopram and suicidality in adult depression and anxiety. ( Pedersen, AG, 2005) |
| "Escitalopram oxalate (S-citalopram, Lexapro), a selective serotonin re-uptake inhibitor antidepressant which is the S-enantiomer of citalopram, is in clinical development worldwide for the treatment of depression and anxiety disorders." | 4.81 | Escitalopram. ( Burke, WJ, 2002) |
| "For the first time, this study analyzed how the DHPC affected the prescription of citalopram and escitalopram in patients with anxiety disorders." | 4.12 | [Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders]. ( Belz, M; Degner, D; Greil, W; Grohmann, R; Köberle, U, 2022) |
| "To characterize the association between functional impairment and major depression subtypes at baseline and to characterize changes in subtypes by functional impairment level in women receiving citalopram in level 1 of the Sequenced Treatment Alternatives to Relieve Depression trial." | 3.83 | Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis. ( Lapane, KL; Rothschild, AJ; Ulbricht, CM, 2016) |
| "The study revealed that patients treated with escitalopram had a reduction of psycho-diagnostic test scores that measure depression and anxiety levels as well as the values of pruritus." | 3.80 | Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study. ( Agnoletti, AF; Betti, S; Campolmi, E; Cossidente, A; D'Erme, AM; Lotti, T; Santosuosso, U; Zanieri, F, 2014) |
| "The purpose of this study was to evaluate the association between polymorphisms in two serotonin pathway genes and the clinical response to citalopram among children and adolescents with depression and/or anxiety disorders." | 3.79 | Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. ( Apter, A; Brent, D; Carmel, M; Frisch, A; Kronenberg, S; Rotberg, B; Weizman, A; Zalsman, G, 2013) |
| "Information processing bias was evaluated in a sample of 25 older adults with generalized anxiety disorder (GAD) over the course of 12 weeks of escitalopram pharmacotherapy." | 3.79 | Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder. ( Nguyen, H; Petkus, AJ; Steiner, AR; Wetherell, JL, 2013) |
| "The aim of this observational study was to evaluate the effectiveness of escitalopram in a naturalistic sample of employed people with mood and anxiety disorders." | 3.74 | Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria. ( Kasper, S; Moser, U; Pjrek, E; Winkler, D, 2007) |
| "Charts of 17 adolescent patients treated naturalistically with citalopram for various anxiety disorders were reviewed." | 3.71 | Citalopram for the treatment of adolescent anxiety disorders: a pilot study. ( Bostic, JQ; Brown, K; Monuteaux, M; Place, S; Prince, JB, 2002) |
| "Escitalopram was superior to placebo for mean ± SD baseline-to-endpoint change in PARS (-8." | 2.94 | Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study. ( Cecil, K; DelBello, MP; Desta, Z; Mills, JA; Mossman, SA; Poweleit, EA; Ramsey, LB; Schroeder, H; Strawn, JR; Varney, ST, 2020) |
| "Participants with GAD and coprescribed benzodiazepines were treated with a lower mean dosage of escitalopram and were less likely to complete the trial; there was no difference in adherence or treatment response." | 2.94 | Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes. ( Altmann, H; Blumberger, DM; Gebara, MA; Karp, JF; Lenze, EJ; Mulsant, BH; Reynolds, CF; Stahl, ST, 2020) |
| " Agomelatine was well-tolerated, with a lower incidence of adverse events than escitalopram." | 2.87 | 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder. ( Ahokas, A; Bauer, M; Bitter, I; de Bodinat, C; Hӧschl, C; Jarema, M; Khoo, JP; Matharan, S; Mosolov, SN; Olivier, V; Picarel-Blanchot, F; Stein, DJ; Van Ameringen, M; Vavrusova, L, 2018) |
| "Citalopram-treated subjects showed significantly greater improvement in reappraisal ability than CBT-waitlisted subjects." | 2.84 | Emotional Reactivity and Regulation Following Citalopram Therapy in Children and Adolescents with Anxiety Disorders. ( Apter, A; Benaroya-Milshtein, N; Carthy, T; Valevski, A, 2017) |
| "Most patients with major depressive disorder (MDD) report clinically significant sleep problems." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| " Side effects were assessed using the Udvalg fur Kliniske Undersøgelser side-effect rating scale." | 2.79 | Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial. ( Dixon, D; Doré, PM; Garfield, LD; Kristjansson, SD; Lenze, EJ; Lotrich, FE; Nowotny, P; Pollock, BG, 2014) |
| "Escitalopram was similarly efficacious but was accompanied by a higher incidence of adverse events compared to placebo." | 2.79 | Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study. ( Ahokas, A; Albarran, C; Avedisova, AS; Höschl, C; Jarema, M; Márquez, MS; Oh, KS; Olivier, V; Stein, DJ, 2014) |
| "Among 811 adults with moderate-to-severe depression, melancholic, atypical, anxious and anxious-somatizing depression subtypes established at baseline were evaluated as predictors of outcome of treatment with flexible dosage of the SSRI escitalopram or the tricyclic antidepressant nortriptyline." | 2.76 | Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline. ( Aitchison, KJ; Dernovsek, MZ; Farmer, A; Hauser, J; Henigsberg, N; Kalember, P; Maier, W; McGuffin, P; Mendlewicz, J; Mors, O; Placentino, A; Rietschel, M; Souery, D; Uher, R; Zobel, A, 2011) |
| "Time to suicidal ideation was significantly longer in patients allocated to SSRI compared to those allocated to IPT (HR = 2." | 2.76 | Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial. ( Calugi, S; Cassano, GB; Fagiolini, A; Frank, E; Miniati, M; Rucci, P; Scocco, P, 2011) |
| "More than half of older adults with major depressive disorder require extended treatment because of incomplete response during acute treatment." | 2.75 | Anxiety impairs depression remission in partial responders during extended treatment in late-life. ( Andreescu, C; Dew, MA; Greenlee, A; Houck, P; Karp, JF; Reynolds, CF, 2010) |
| "To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD." | 2.73 | Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder. ( Huang, H; Kinrys, G; Krishnan, R; Krystal, A; McCall, WV; Pollack, M; Roach, J; Roth, T; Rubens, R; Schaefer, K, 2008) |
| "About half of outpatients with major depressive disorder also have clinically meaningful levels of anxiety." | 2.73 | Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. ( Alpert, JE; Balasubramani, GK; Biggs, MM; Carmin, CN; Fava, M; Howland, R; Leuchter, A; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2008) |
| "Escitalopram was administered over a 12-week treatment period to 790 depressed patients, including 482 patients with at least one concomitant anxiety disorder." | 2.73 | A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. ( Galinowski, A; Ménard, F; Olié, JP; Tonnoir, B, 2007) |
| "Escitalopram was better tolerated." | 2.73 | Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. ( Bose, A; Gommoll, C; Korotzer, A; Li, D, 2008) |
| "Escitalopram has proven efficacy in the short-term treatment of SAD and prevention of relapse." | 2.73 | Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder. ( Aballéa, S; Auquier, P; Despiegel, N; François, C; Montgomery, SA; Roïz, J, 2008) |
| "Escitalopram was significantly superior to placebo in all comparisons." | 2.73 | Escitalopram in the treatment of anxiety symptoms associated with depression. ( Andersen, HF; Bandelow, B; Dolberg, OT, 2007) |
| "Escitalopram was well tolerated and 7% of the escitalopram-treated patients withdrew due to adverse events, vs." | 2.72 | Prevention of relapse in generalized anxiety disorder by escitalopram treatment. ( Allgulander, C; Florea, I; Huusom, AK, 2006) |
| "Escitalopram 20 mg was significantly more effective than paroxetine 20 mg on 5 of the 6 symptom dimensions." | 2.72 | Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions. ( Andersen, EW; Lader, M; Stein, DJ, 2006) |
| "Escitalopram was efficacious in generalised anxiety disorder, 20 was not significantly superior to 10 mg/day." | 2.72 | Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. ( Baldwin, DS; Huusom, AK; Maehlum, E, 2006) |
| "Escitalopram has previously been shown to be effective and well tolerated in the acute treatment of GAD." | 2.71 | Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder. ( Bose, A; Davidson, JR; Wang, Q, 2005) |
| "All of the patients with primary conversion disorder had a current or previous depressive or anxiety disorder compared with 40% (N = 2) of the patients with additional somatoform diagnoses." | 2.71 | Antidepressant treatment outcomes of psychogenic movement disorder. ( Lang, AE; Voon, V, 2005) |
| "Escitalopram 10 mg/day is an effective and well-tolerated antidepressant." | 2.71 | Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. ( Bose, A; Goodman, WK; Wang, Q, 2005) |
| "Escitalopram has been shown in clinical trials to improve anxiety symptoms associated with depression, panic disorder, and social anxiety disorder." | 2.71 | Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. ( Bose, A; Davidson, JR; Korotzer, A; Zheng, H, 2004) |
| "Citalopram therapy was well tolerated, and more than one half of the patients who began treatment improved significantly." | 2.70 | Citalopram treatment of paroxetine-intolerant depressed patients. ( Ferguson, JM; Lydiard, RB; Thase, ME; Wilcox, CS, 2002) |
| "Citalopram, a newer SSRI used in the treatment of depression, has not been studied for GAD." | 2.70 | Treatment of generalized anxiety disorder with citalopram. ( Rauscher, F; Varia, I, 2002) |
| "Mirtazapine treatment was also related to faster improvement of sleep, quality of sleep and improved alertness following awakening, as shown by statistically significant differences on the self-rating LSEQ at various time points." | 2.69 | Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. ( Agren, H; Behnke, K; Helsdingen, JT; Leinonen, E; Skarstein, J, 1999) |
| "Disturbed sleep is a key symptom in major depressive disorder (MDD) and generalized anxiety disorder (GAD)." | 2.47 | Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder. ( Lopez, AG; Stein, DJ, 2011) |
| "Escitalopram has low protein binding (56%) and is not likely to cause interactions with highly protein-bound drugs." | 2.44 | The clinical pharmacokinetics of escitalopram. ( Rao, N, 2007) |
| "Escitalopram has a straightforward pharmacokinetic profile, little effect on hepatic metabolism, and is relatively safe in overdose." | 2.43 | Managing depressive and anxiety disorders with escitalopram. ( Thase, ME, 2006) |
| "Escitalopram is a new antidepressant drug, available for clinical use in many countries." | 2.41 | Escitalopram: efficacy and tolerability in the treatment of depression. ( Baldwin, DS, 2002) |
| "Citalopram is a selective serotonin re-uptake inhibitor that has demonstrated antidepressant efficacy in numerous controlled clinical trials." | 2.41 | Citalopram: a comprehensive review. ( Pollock, BG, 2001) |
| "Mirtazapine has intrinsic receptor-blocking properties (in particular, serotonin-2 [5-HT2] receptor blockade) that can be linked to an early relief of anxiety symptoms during the treatment." | 2.40 | Care of depressed patients with anxiety symptoms. ( Nutt, DJ, 1999) |
| "Fifty-one females with major depressive disorder or anxiety disorder were stratified into three groups: 1) those treated with SSRIs <23 years of age, 2) those treated with SSRIs >23 years of age, and 3) those that were never treated with SSRIs." | 1.56 | The influence of age-of-onset of antidepressant use on the acute CBF response to a citalopram challenge; a pharmacological MRI study. ( Homberg, JR; Lucassen, PJ; Reneman, L; Schrantee, A; Solleveld, MM, 2020) |
| "Escitalopram 10 mg was prescribed to the patients." | 1.46 | Effects of Selective Seratonine Re-Uptake Inhibitors on Meniere's Disease. ( Kıroğlu, M; Kıroğlu, O; Sürmelioğlu, Ö, 2017) |
| "Citalopram was continued and spontaneous improvement was noticed in the following weeks." | 1.43 | Citalopram-induced dyskinesia of the tongue: a video presentation. ( Gaanderse, M; Kliffen, J; Linssen, W, 2016) |
| "Escitalopram was associated with a significantly greater improvement in depressive symptoms, along with a significantly lower number and duration of sick-leave certificates." | 1.37 | [Depression and professional activity: results of the NEXTEP study]. ( Biro, G; Caparros Panduro, C; Dardennes, R; Raffaitin, F, 2011) |
| "Escitalopram was associated with higher expected number of SFDs than paroxetine (86." | 1.35 | Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada. ( Bereza, BG; Einarson, TR; Iskedjian, M; Le Melledo, JM; Walker, JH, 2008) |
| "Thirty youth with major depressive disorder (MDD) and 23 control youth reported on caffeine use, sleep, and affect in their natural environment using ecological momentary assessment at baseline and over 8 weeks, while MDD youth received treatment." | 1.35 | Caffeine consumption, sleep, and affect in the natural environments of depressed youth and healthy controls. ( Axelson, DA; Birmaher, B; Dahl, RE; Forbes, EE; Ryan, ND; Semel, M; Silk, JS; Whalen, DJ, 2008) |
| "The diagnoses of ADHD and tic disorder were based on clinical observations and standardized rating scales." | 1.34 | Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. ( Harris, DK; Párraga, HC; Párraga, MI, 2007) |
| "Escitalopram-treated patients were associated with 14." | 1.33 | Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom. ( Baldwin, DS; Despiegel, N; Drost, PB; Hemels, ME; Jørgensen, TR; Stein, DJ, 2006) |
| "Citalopram was administered for 8 weeks to the 83 patients who completed this study." | 1.33 | Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. ( Choi, MJ; Kang, RH; Lee, MS; Lim, SW; Oh, KS, 2006) |
| "One hundred sixty-five patients with cancer, consecutively admitted to the Oncology Division of San Camillo-Forlanini Hospital, were recruited to the study." | 1.33 | Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division. ( Biondi, M; Cairoli, F; Costantini, A; Ferrarese, G; Pasquini, M; Picardi, A; Sternberg, C, 2006) |
| "Citalopram treatment resulted in significant deactivation (p = 0." | 1.32 | Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram. ( Carey, PD; Harvey, BH; Niehaus, DJ; Seedat, S; Stein, DJ; van der Linden, G; van Heerden, BB; Warwick, J, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (2.13) | 18.2507 |
| 2000's | 86 (45.74) | 29.6817 |
| 2010's | 86 (45.74) | 24.3611 |
| 2020's | 12 (6.38) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, G | 2 |
| Marston, L | 1 |
| Duffy, L | 1 |
| Freemantle, N | 1 |
| Gilbody, S | 1 |
| Hunter, R | 1 |
| Kendrick, T | 1 |
| Kessler, D | 1 |
| Mangin, D | 1 |
| King, M | 1 |
| Lanham, P | 1 |
| Moore, M | 1 |
| Nazareth, I | 1 |
| Wiles, N | 1 |
| Bacon, F | 1 |
| Bird, M | 1 |
| Brabyn, S | 1 |
| Burns, A | 1 |
| Clarke, CS | 1 |
| Hunt, A | 1 |
| Pervin, J | 1 |
| Simonoff, E | 1 |
| Mowlem, F | 1 |
| Pearson, O | 1 |
| Anagnostou, E | 1 |
| Donnelly, C | 1 |
| Hollander, E | 1 |
| King, BH | 1 |
| McCracken, JT | 1 |
| Scahill, L | 1 |
| Sikich, L | 1 |
| Pickles, A | 1 |
| Köberle, U | 1 |
| Grohmann, R | 1 |
| Belz, M | 1 |
| Greil, W | 1 |
| Degner, D | 1 |
| Strawn, JR | 3 |
| Moldauer, L | 1 |
| Hahn, RD | 1 |
| Wise, A | 1 |
| Bertzos, K | 1 |
| Eisenberg, B | 1 |
| Greenberg, E | 1 |
| Liu, C | 1 |
| Gopalkrishnan, M | 1 |
| McVoy, M | 1 |
| Knutson, JA | 1 |
| Frick, A | 2 |
| Engman, J | 2 |
| Alaie, I | 2 |
| Björkstrand, J | 2 |
| Gingnell, M | 2 |
| Larsson, EM | 2 |
| Eriksson, E | 1 |
| Wahlstedt, K | 2 |
| Fredrikson, M | 2 |
| Furmark, T | 2 |
| Hoge, EA | 1 |
| Bui, E | 1 |
| Mete, M | 1 |
| Philip, SR | 1 |
| Gabriel, C | 1 |
| Ward, MJ | 1 |
| Suzuki, R | 1 |
| Dutton, MA | 1 |
| Simon, NM | 1 |
| Solleveld, MM | 1 |
| Schrantee, A | 1 |
| Homberg, JR | 1 |
| Lucassen, PJ | 1 |
| Reneman, L | 1 |
| Mills, JA | 2 |
| Schroeder, H | 1 |
| Mossman, SA | 2 |
| Varney, ST | 2 |
| Ramsey, LB | 2 |
| Poweleit, EA | 1 |
| Desta, Z | 1 |
| Cecil, K | 1 |
| DelBello, MP | 2 |
| Altmann, H | 1 |
| Stahl, ST | 1 |
| Gebara, MA | 1 |
| Lenze, EJ | 14 |
| Mulsant, BH | 4 |
| Blumberger, DM | 1 |
| Reynolds, CF | 8 |
| Karp, JF | 5 |
| Hassan Basri, M | 1 |
| Khoo, CS | 1 |
| Che Hamzah, J | 1 |
| Lu, L | 1 |
| Li, H | 1 |
| Schroeder, HK | 1 |
| Cecil, KM | 1 |
| Huang, X | 1 |
| Gong, Q | 1 |
| Sweeney, JA | 1 |
| Shen, Z | 4 |
| Wang, F | 1 |
| Cui, L | 1 |
| Ren, L | 3 |
| Hong, X | 1 |
| Yuan, Y | 3 |
| Shen, X | 4 |
| Kıroğlu, O | 1 |
| Sürmelioğlu, Ö | 1 |
| Kıroğlu, M | 1 |
| Mitra, S | 1 |
| Singh, M | 1 |
| Sinha, V | 1 |
| Anwar, Z | 1 |
| Koek, W | 1 |
| Mitchell, NC | 1 |
| Daws, LC | 1 |
| Qian, M | 3 |
| Lin, M | 2 |
| Guan, T | 1 |
| Yang, J | 1 |
| Li, L | 1 |
| Fang, Y | 1 |
| Qiu, Q | 1 |
| Zhang, S | 1 |
| Sun, L | 1 |
| Li, G | 1 |
| Xiao, S | 1 |
| Li, X | 1 |
| Fong, SY | 1 |
| Wing, YK | 1 |
| Morrissey, H | 1 |
| Pradhan, T | 1 |
| Stein, DJ | 10 |
| Khoo, JP | 1 |
| Ahokas, A | 2 |
| Jarema, M | 2 |
| Van Ameringen, M | 2 |
| Vavrusova, L | 1 |
| Hӧschl, C | 1 |
| Bauer, M | 1 |
| Bitter, I | 1 |
| Mosolov, SN | 1 |
| Olivier, V | 2 |
| Matharan, S | 1 |
| Picarel-Blanchot, F | 1 |
| de Bodinat, C | 1 |
| Fountoulakis, KN | 1 |
| Karavelas, V | 1 |
| Moysidou, S | 1 |
| Mavridis, D | 1 |
| Pastiadis, K | 1 |
| Petalidou, N | 1 |
| Nimatoudis, I | 1 |
| Kasper, S | 3 |
| He, Q | 1 |
| Wang, X | 1 |
| Zhu, J | 2 |
| Yoon, W | 1 |
| Shon, SH | 1 |
| Hong, Y | 1 |
| Joo, YH | 1 |
| Lee, JS | 1 |
| Cai, M | 1 |
| Zhang, Z | 1 |
| Hornboll, B | 1 |
| Macoveanu, J | 1 |
| Nejad, A | 1 |
| Rowe, J | 1 |
| Elliott, R | 1 |
| Knudsen, GM | 1 |
| Siebner, HR | 1 |
| Paulson, OB | 1 |
| Roselle, A | 1 |
| Hou, R | 1 |
| Ye, G | 1 |
| Liu, Y | 1 |
| Chen, X | 1 |
| Pan, M | 1 |
| Zhu, F | 1 |
| Fu, J | 1 |
| Fu, T | 1 |
| Liu, Q | 1 |
| Gao, Z | 1 |
| Baldwin, DS | 11 |
| Tang, Z | 1 |
| Thorkelson, G | 1 |
| Laughlin, SF | 1 |
| Turner, KS | 1 |
| Ober, N | 1 |
| Handen, BL | 1 |
| Kolli, V | 1 |
| Addula, M | 1 |
| Balasubramaniam, M | 1 |
| Joshi, P | 1 |
| Alag, P | 1 |
| Gupta, S | 1 |
| Maher, S | 1 |
| Tampi, D | 1 |
| Gupta, A | 1 |
| Young, J | 1 |
| Tampi, RR | 1 |
| Rotberg, B | 1 |
| Kronenberg, S | 4 |
| Carmel, M | 4 |
| Frisch, A | 4 |
| Brent, D | 4 |
| Zalsman, G | 1 |
| Apter, A | 5 |
| Weizman, A | 4 |
| Di Simplicio, M | 1 |
| Norbury, R | 1 |
| Reinecke, A | 1 |
| Harmer, CJ | 4 |
| Peh, AL | 1 |
| Nieng, CH | 1 |
| Ling, YH | 1 |
| Kheng, TW | 1 |
| Neng, TS | 1 |
| Koon, OG | 1 |
| Wetherell, JL | 5 |
| Petkus, AJ | 2 |
| White, KS | 3 |
| Nguyen, H | 3 |
| Kornblith, S | 2 |
| Andreescu, C | 10 |
| Zisook, S | 3 |
| Barlow, DH | 1 |
| Comer, JS | 1 |
| Hanck, L | 1 |
| Schellekens, AF | 1 |
| Tempesta, D | 1 |
| Mazza, M | 1 |
| Serroni, N | 1 |
| Moschetta, FS | 1 |
| Di Giannantonio, M | 1 |
| Ferrara, M | 1 |
| De Berardis, D | 1 |
| Garfield, LD | 1 |
| Dixon, D | 4 |
| Nowotny, P | 3 |
| Lotrich, FE | 1 |
| Pollock, BG | 6 |
| Kristjansson, SD | 1 |
| Doré, PM | 2 |
| Mikami, K | 1 |
| Jorge, RE | 1 |
| Moser, DJ | 1 |
| Arndt, S | 1 |
| Jang, M | 1 |
| Solodkin, A | 1 |
| Small, SL | 1 |
| Fonzetti, P | 1 |
| Hegel, MT | 1 |
| Robinson, RG | 1 |
| Márquez, MS | 1 |
| Höschl, C | 1 |
| Oh, KS | 2 |
| Avedisova, AS | 1 |
| Albarran, C | 1 |
| Elnazer, HY | 1 |
| Jakubovski, E | 1 |
| Bloch, MH | 1 |
| Sheu, LK | 1 |
| Tudorascu, D | 1 |
| Gross, JJ | 1 |
| Walker, S | 1 |
| Banihashemi, L | 1 |
| Aizenstein, H | 1 |
| Praharaj, SK | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 5 |
| Luther, JF | 1 |
| Trivedi, MH | 4 |
| Rush, AJ | 4 |
| Altieri, SC | 1 |
| Yang, H | 1 |
| O'Brien, HJ | 1 |
| Redwine, HM | 1 |
| Senturk, D | 2 |
| Hensler, JG | 1 |
| Andrews, AM | 1 |
| Lavretsky, H | 1 |
| Reinlieb, M | 1 |
| St Cyr, N | 1 |
| Siddarth, P | 1 |
| Ercoli, LM | 1 |
| Yoo, I | 1 |
| Woo, JM | 1 |
| Lee, SH | 2 |
| Fava, M | 5 |
| Mischoulon, D | 1 |
| Papakostas, GI | 1 |
| Kim, EJ | 1 |
| Chung, S | 1 |
| Ha, JH | 1 |
| Jeon, HJ | 1 |
| Giger, R | 1 |
| Nisa, L | 1 |
| Ulbricht, CM | 2 |
| Rothschild, AJ | 2 |
| Lapane, KL | 2 |
| Carthy, T | 1 |
| Benaroya-Milshtein, N | 1 |
| Valevski, A | 1 |
| Rosnick, CB | 1 |
| Dowling, NA | 1 |
| Merkouris, SS | 1 |
| Lorains, FK | 1 |
| Amitai, M | 1 |
| Michaelovsky, E | 1 |
| Chen, A | 1 |
| Fennig, S | 1 |
| Faria, V | 1 |
| Carlbring, P | 1 |
| Andersson, G | 1 |
| Reis, M | 1 |
| Tolentino, JC | 1 |
| Schmidt, JJ | 1 |
| Schmidt, GJ | 1 |
| Mesquita, CT | 1 |
| Schmidt, SL | 1 |
| Norton, DJ | 1 |
| Cates, C | 1 |
| Jukić, MM | 1 |
| Opel, N | 1 |
| Ström, J | 1 |
| Carrillo-Roa, T | 1 |
| Miksys, S | 1 |
| Novalen, M | 1 |
| Renblom, A | 1 |
| Sim, SC | 1 |
| Peñas-Lledó, EM | 1 |
| Courtet, P | 1 |
| Llerena, A | 1 |
| Baune, BT | 1 |
| de Quervain, DJ | 1 |
| Papassotiropoulos, A | 1 |
| Tyndale, RF | 1 |
| Binder, EB | 1 |
| Dannlowski, U | 1 |
| Ingelman-Sundberg, M | 1 |
| Gaanderse, M | 1 |
| Kliffen, J | 1 |
| Linssen, W | 1 |
| Jacobsen, JP | 1 |
| Weikop, P | 1 |
| Hansen, HH | 1 |
| Mikkelsen, JD | 1 |
| Redrobe, JP | 1 |
| Holst, D | 1 |
| Bond, CT | 1 |
| Adelman, JP | 1 |
| Christophersen, P | 1 |
| Mirza, NR | 1 |
| Demyttenaere, K | 1 |
| Andersen, HF | 4 |
| Reines, EH | 2 |
| François, C | 2 |
| Montgomery, SA | 2 |
| Despiegel, N | 4 |
| Aballéa, S | 1 |
| Roïz, J | 1 |
| Auquier, P | 2 |
| Pelissolo, A | 1 |
| Rollman, BL | 3 |
| Shear, MK | 6 |
| Dew, MA | 5 |
| Ciliberti, C | 1 |
| Costantino, M | 1 |
| Snyder, S | 1 |
| Shi, P | 3 |
| Spitznagel, E | 1 |
| Butters, MA | 4 |
| Husain, MM | 1 |
| McClintock, SM | 1 |
| Nierenberg, AA | 1 |
| Davis, L | 1 |
| Balasubramani, GK | 3 |
| Young, E | 1 |
| Albala, AA | 1 |
| Montes, ML | 1 |
| Fraile, JM | 1 |
| González, JJ | 1 |
| Arribas, JR | 1 |
| Wienberg, M | 1 |
| Glenthoj, BY | 1 |
| Jensen, KS | 1 |
| Oranje, B | 1 |
| Dolberg, OT | 5 |
| Bandelow, B | 4 |
| Pollack, MH | 1 |
| Klein, DN | 1 |
| Arnow, BA | 1 |
| Barkin, JL | 1 |
| Dowling, F | 1 |
| Kocsis, JH | 1 |
| Leon, AC | 1 |
| Manber, R | 1 |
| Rothbaum, BO | 1 |
| Asnis, GM | 1 |
| Shrivastava, R | 1 |
| Lydiard, B | 1 |
| Bastani, B | 1 |
| Sheehan, D | 1 |
| Roth, T | 2 |
| Gale, CK | 1 |
| Millichamp, J | 1 |
| Schwan, S | 1 |
| Hallberg, P | 1 |
| van Veen, JF | 1 |
| van Vliet, IM | 1 |
| de Rijk, RH | 1 |
| van Pelt, J | 1 |
| Mertens, B | 1 |
| Fekkes, D | 1 |
| Zitman, FG | 1 |
| Pandey, DK | 1 |
| Yadav, SK | 1 |
| Mahesh, R | 1 |
| Rajkumar, R | 1 |
| Skidmore, E | 1 |
| Lotz, M | 1 |
| Lenze, E | 1 |
| Schirman, S | 2 |
| Melhem, N | 2 |
| Pick, N | 2 |
| Gothelf, D | 2 |
| Thase, ME | 4 |
| Muhtz, C | 1 |
| Agorastos, A | 1 |
| Kellner, M | 1 |
| Bech, P | 1 |
| Lönn, SL | 1 |
| Overø, KF | 1 |
| McCabe, C | 1 |
| Mishor, Z | 1 |
| Cowen, PJ | 2 |
| Greenlee, A | 1 |
| Houck, P | 2 |
| Coric, V | 1 |
| Feldman, HH | 1 |
| Oren, DA | 1 |
| Shekhar, A | 1 |
| Pultz, J | 1 |
| Dockens, RC | 1 |
| Wu, X | 1 |
| Gentile, KA | 1 |
| Huang, SP | 1 |
| Emison, E | 1 |
| Delmonte, T | 1 |
| D'Souza, BB | 1 |
| Zimbroff, DL | 1 |
| Grebb, JA | 1 |
| Goddard, AW | 1 |
| Stock, EG | 1 |
| Hollingworth, SA | 1 |
| Burgess, PM | 1 |
| Whiteford, HA | 1 |
| Schneier, FR | 1 |
| Belzer, KD | 1 |
| Kishon, R | 1 |
| Amsel, L | 1 |
| Simpson, HB | 1 |
| Fiedorowicz, JG | 1 |
| Hale, N | 1 |
| Spector, AA | 1 |
| Coryell, WH | 1 |
| Mantella, RC | 2 |
| Goate, AM | 2 |
| Thompson, PA | 2 |
| Stoddard, JA | 1 |
| Hahn, A | 1 |
| Lanzenberger, R | 1 |
| Wadsak, W | 1 |
| Spindelegger, C | 1 |
| Moser, U | 2 |
| Mien, LK | 1 |
| Mitterhauser, M | 1 |
| Chauvet-Gélinier, JC | 1 |
| Park, YM | 1 |
| Kim, DW | 1 |
| Kim, S | 1 |
| Im, CH | 1 |
| Cassimjee, N | 1 |
| Fouche, JP | 1 |
| Burnett, M | 1 |
| Lochner, C | 1 |
| Warwick, J | 2 |
| Dupont, P | 1 |
| Cloete, KJ | 1 |
| Carey, PD | 2 |
| Bies, RR | 1 |
| Lotrich, FK | 1 |
| Silk, JS | 2 |
| Forbes, EE | 2 |
| Whalen, DJ | 2 |
| Jakubcak, JL | 1 |
| Thompson, WK | 1 |
| Ryan, ND | 2 |
| Axelson, DA | 2 |
| Birmaher, B | 3 |
| Dahl, RE | 2 |
| Pierò, A | 1 |
| Locati, E | 1 |
| Rucci, P | 1 |
| Frank, E | 2 |
| Scocco, P | 1 |
| Calugi, S | 1 |
| Miniati, M | 1 |
| Fagiolini, A | 2 |
| Cassano, GB | 1 |
| Hsu, WY | 1 |
| Huang, SS | 1 |
| Chiu, NY | 1 |
| Raffaitin, F | 1 |
| Caparros Panduro, C | 1 |
| Biro, G | 1 |
| Dardennes, R | 1 |
| Uher, R | 1 |
| Dernovsek, MZ | 1 |
| Mors, O | 1 |
| Hauser, J | 1 |
| Souery, D | 1 |
| Zobel, A | 1 |
| Maier, W | 1 |
| Henigsberg, N | 1 |
| Kalember, P | 1 |
| Rietschel, M | 1 |
| Placentino, A | 1 |
| Mendlewicz, J | 1 |
| Aitchison, KJ | 1 |
| McGuffin, P | 1 |
| Farmer, A | 1 |
| Newcomer, JW | 1 |
| Bhalla, RK | 1 |
| Mantella, R | 1 |
| Begley, AE | 1 |
| Browning, M | 1 |
| Grol, M | 1 |
| Ly, V | 1 |
| Goodwin, GM | 2 |
| Holmes, EA | 1 |
| de Knegt, RJ | 1 |
| Bezemer, G | 1 |
| Van Gool, AR | 1 |
| Drenth, JP | 1 |
| Hansen, BE | 1 |
| Droogleever Fortuyn, HA | 1 |
| Weegink, CJ | 1 |
| Hengeveld, MW | 1 |
| Janssen, HL | 1 |
| Lopez, AG | 1 |
| Verma, R | 1 |
| Balhara, YP | 1 |
| Deshpande, SN | 1 |
| Rickels, K | 1 |
| Shiovitz, TM | 1 |
| Ramey, TS | 1 |
| Weaver, JJ | 1 |
| Knapp, LE | 1 |
| Miceli, JJ | 1 |
| Farabaugh, A | 1 |
| Alpert, J | 1 |
| Otto, MW | 1 |
| Baer, L | 1 |
| Perlis, R | 1 |
| Friedman, E | 1 |
| Nyer, M | 1 |
| Bitran, S | 1 |
| Inamori, A | 1 |
| Trivedi, M | 1 |
| D'Erme, AM | 1 |
| Zanieri, F | 1 |
| Campolmi, E | 1 |
| Santosuosso, U | 1 |
| Betti, S | 1 |
| Agnoletti, AF | 1 |
| Cossidente, A | 1 |
| Lotti, T | 1 |
| Griebel, G | 1 |
| Beeské, S | 1 |
| Stahl, SM | 1 |
| Farrokhi, F | 1 |
| Hosseini, SH | 1 |
| Espahbodi, F | 1 |
| Mirzadeh Goudarzi, SM | 1 |
| Steiner, AR | 1 |
| Rostami, Z | 1 |
| Einollahi, B | 1 |
| Burke, WJ | 2 |
| Ferguson, JM | 1 |
| Lydiard, RB | 1 |
| Wilcox, CS | 1 |
| Prince, JB | 1 |
| Bostic, JQ | 1 |
| Monuteaux, M | 1 |
| Brown, K | 1 |
| Place, S | 1 |
| Woolley, JB | 1 |
| Heyman, I | 1 |
| Waugh, J | 1 |
| Goa, KL | 1 |
| Shelley, NC | 1 |
| Hoehn-Saric, R | 1 |
| Schlund, MW | 1 |
| Wong, SH | 1 |
| Davidson, JR | 2 |
| Bose, A | 4 |
| Korotzer, A | 2 |
| Zheng, H | 1 |
| Campo, JV | 1 |
| Perel, J | 1 |
| Lucas, A | 1 |
| Bridge, J | 1 |
| Ehmann, M | 1 |
| Kalas, C | 1 |
| Monk, K | 1 |
| Axelson, D | 1 |
| Ryan, N | 1 |
| Di Lorenzo, C | 1 |
| Brent, DA | 1 |
| Niehaus, DJ | 1 |
| van der Linden, G | 1 |
| van Heerden, BB | 1 |
| Harvey, BH | 1 |
| Seedat, S | 1 |
| Miller, MD | 2 |
| Tracey, B | 2 |
| Pedersen, AG | 2 |
| Malin, P | 1 |
| Wengel, SP | 1 |
| Mullins, CD | 2 |
| Shaya, FT | 2 |
| Meng, F | 2 |
| Wang, J | 2 |
| Harrison, D | 1 |
| Blank, S | 2 |
| Houck, PR | 2 |
| Cyranowski, JM | 1 |
| Swartz, H | 1 |
| Scott, J | 1 |
| Kupfer, DJ | 1 |
| Goodman, WK | 1 |
| Wang, Q | 2 |
| Andersen, EW | 1 |
| Lader, M | 2 |
| Nair, RV | 1 |
| Marchesi, C | 2 |
| Cantoni, A | 2 |
| Fontò, S | 2 |
| Giannelli, MR | 2 |
| Maggini, C | 2 |
| Kruszewski, SP | 1 |
| Allgulander, C | 2 |
| Florea, I | 1 |
| Huusom, AK | 2 |
| Nil, R | 1 |
| Voon, V | 1 |
| Lang, AE | 1 |
| Bron, MS | 1 |
| Grant, JE | 1 |
| Potenza, MN | 1 |
| Balon, R | 1 |
| Pasquini, M | 1 |
| Biondi, M | 1 |
| Costantini, A | 1 |
| Cairoli, F | 1 |
| Ferrarese, G | 1 |
| Picardi, A | 1 |
| Sternberg, C | 1 |
| Maehlum, E | 1 |
| Dhillon, S | 1 |
| Scott, LJ | 1 |
| Plosker, GL | 1 |
| Choi, MJ | 1 |
| Kang, RH | 1 |
| Lim, SW | 1 |
| Lee, MS | 1 |
| Jørgensen, TR | 1 |
| Drost, PB | 1 |
| Hemels, ME | 1 |
| Olié, JP | 1 |
| Tonnoir, B | 1 |
| Ménard, F | 1 |
| Galinowski, A | 1 |
| Mohamed, S | 1 |
| Osatuke, K | 1 |
| Aslam, M | 1 |
| Kasckow, J | 1 |
| Grover, S | 1 |
| Biswas, P | 1 |
| Bhateja, G | 1 |
| Kulhara, P | 1 |
| Rao, N | 1 |
| Winkler, D | 1 |
| Pjrek, E | 1 |
| Brown, ES | 1 |
| Vornik, LA | 1 |
| Khan, DA | 1 |
| Mancini, C | 1 |
| Patterson, B | 1 |
| Bennett, M | 1 |
| Jørgensen, T | 1 |
| Wade, A | 1 |
| Toumi, M | 1 |
| Guiton, C | 1 |
| Weiller, E | 2 |
| Bareggi, SR | 1 |
| Mundo, E | 1 |
| Dell'Osso, B | 1 |
| Altamura, AC | 1 |
| Semel, M | 1 |
| Gommoll, C | 1 |
| Li, D | 1 |
| Lecrubier, Y | 1 |
| Alpert, JE | 1 |
| Carmin, CN | 1 |
| Biggs, MM | 1 |
| Leuchter, A | 1 |
| Howland, R | 1 |
| Warden, D | 1 |
| Nelson, JC | 1 |
| Bystritsky, A | 1 |
| Kerwin, L | 1 |
| Feusner, JD | 1 |
| Vapnik, T | 1 |
| Iskedjian, M | 1 |
| Walker, JH | 1 |
| Bereza, BG | 1 |
| Le Melledo, JM | 1 |
| Einarson, TR | 1 |
| Párraga, HC | 1 |
| Párraga, MI | 1 |
| Harris, DK | 1 |
| Pollack, M | 1 |
| Kinrys, G | 1 |
| Krystal, A | 1 |
| McCall, WV | 1 |
| Schaefer, K | 1 |
| Rubens, R | 1 |
| Roach, J | 1 |
| Huang, H | 1 |
| Krishnan, R | 1 |
| Oulis, P | 1 |
| Kouzoupis, AV | 1 |
| Koulouris, G | 1 |
| Masdrakis, VG | 1 |
| Kontoangelos, K | 1 |
| Matsoukas, T | 1 |
| Papadimitriou, GN | 1 |
| Ragneskog, H | 1 |
| Eriksson, S | 1 |
| Karlsson, I | 1 |
| Gottfries, CG | 1 |
| Nutt, DJ | 1 |
| Ruiz-Doblado, S | 1 |
| Carrizosa, A | 1 |
| García-Hernández, MJ | 1 |
| Rodríguez-Pichardo, A | 1 |
| Leinonen, E | 1 |
| Skarstein, J | 1 |
| Behnke, K | 1 |
| Agren, H | 1 |
| Helsdingen, JT | 1 |
| Lantz, MS | 1 |
| Varia, IM | 1 |
| Cloutier, CA | 1 |
| Doraiswamy, PM | 1 |
| Varia, I | 1 |
| Rauscher, F | 1 |
| Chavira, DA | 1 |
| Stein, MB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety[NCT02818751] | 84 participants (Actual) | Interventional | 2015-05-31 | Completed | |||
| Incomplete Response in Late Life Depression: Getting to Remission[NCT00892047] | Phase 4 | 468 participants (Actual) | Interventional | 2009-08-31 | Completed | ||
| Pharmacotherapy of Late-Life Generalized Anxiety Disorder[NCT00105586] | Phase 4 | 177 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| CBT Augmentation of SSRI Treatment for Geriatric GAD[NCT00601965] | 73 participants (Actual) | Interventional | 2007-10-31 | Completed | |||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Comparison of Tianeptine Versus Escitalopram for the Treatment of Depression and Cognitive Impairment in Patients With Major Depressive Disorder: A Randomized, Multicenter, Open-label Study[NCT01309776] | Phase 4 | 164 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| Effect of Acupressure on Pain, Anxiety and Vital Signs in Patients With Coronary Angiography: A Randomized Controlled Study[NCT05082506] | 105 participants (Anticipated) | Interventional | 2021-12-15 | Not yet recruiting | |||
| Optimizing Care for Older Adults With Back Pain and Depression[NCT01124188] | Phase 4 | 263 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| The Effect of Seven-Day Atorvastatin Administration on Emotional Processing, Reward Processing, and Inflammation in Healthy Volunteers[NCT03966859] | 50 participants (Actual) | Interventional | 2019-06-19 | Completed | |||
| A Multicenter, Randomized, Double-Blind, Placebo and Escitalopram Controlled Trial of the Safety and Efficacy of Pexacerfont (BMS-562086) in the Treatment of Outpatients With Generalized Anxiety Disorder[NCT00481325] | Phase 2/Phase 3 | 260 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Cognitive-Behavioral Therapy and Pharmacotherapy Augmentation for Generalized Anxiety Disorder: A Pilot Investigation[NCT00219349] | Phase 4 | 25 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Using Smartphones to Enhance the Treatment of Childhood Anxiety[NCT02259036] | 40 participants (Actual) | Interventional | 2014-08-31 | Completed | |||
| Development and Evaluation of an Ecological Momentary Assessment (EMA) Baseline Screening System for Therapists Who Treat Youths With Depressive Symptoms[NCT04830527] | 60 participants (Actual) | Interventional | 2020-11-24 | Terminated (stopped due to The study was terminated early due to the difficulty in recruiting cases during a pandemic period.) | |||
| An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD)[NCT00413010] | Phase 3 | 356 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| A Double-blind, Placebo-controlled Study Evaluating the Pharmacodynamic Effects of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) on Hypothalamic-pituitary-adrenal Axis Function in Outpatients With Major Depressive Disorder[NCT01606384] | Phase 2 | 100 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
| An Eight-Week, Multicenter, Double-Blind, Placebo- and Paroxetine-Controlled Study Evaluating the Efficacy, and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Patients With Major Depressive Disorder[NCT00361491] | Phase 2 | 324 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| An Eight-Week, Multicenter, Double-Blind, Placebo- and Escitalopram-Controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Major Depressive Disorder[NCT00358631] | Phase 2 | 319 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| An Eight-week, Multicenter, Double-blind, Placebo- and Paroxetine-controlled Study Evaluating the Efficacy and Tolerability of Two Fixed Doses of SSR149415 (250 mg Bid and 100 mg Bid) in Outpatients With Generalized Anxiety Disorder[NCT00374166] | Phase 2 | 325 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| Escitalopram as a Treatment for Pain in Polyneuropathy. A Double-Blind, Randomized, Placebo Controlled Trial.[NCT00162968] | Phase 4 | 50 participants | Interventional | 2004-12-31 | Completed | ||
| "Investigation of Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Hot and Cold Cognitive Systems In Treatment Resistant Depression (TRD)"[NCT03977038] | 25 participants (Actual) | Observational [Patient Registry] | 2020-05-30 | Completed | |||
| Anxiety and Recurrent Abdominal Pain in Children[NCT00962039] | Phase 2/Phase 3 | 81 participants (Actual) | Interventional | 2004-07-31 | Completed | ||
| Increasing Access to Evidence-based Treatments for Depression: The Development and Evaluation of a Digital Training Platform for Interpersonal Psychotherapy.[NCT04619615] | 44 participants (Actual) | Interventional | 2020-07-27 | Active, not recruiting | |||
| The WORKER Study: A Randomized Controlled Trial of Escitalopram and Telephone-based Cognitive Behaviour Therapy in Working Patients With Major Depressive Disorder[NCT00702598] | 105 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.[NCT00235508] | Phase 4 | 420 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| Study to Determine Steady-state Level of Citalopram Pharmacokinetic Parameters in Patients With Short Bowel Syndrome[NCT00876226] | 0 participants (Actual) | Interventional | 2010-05-01 | Withdrawn | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants who developed clinically significant akathisia. (NCT00892047)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 26.7 |
| 2: Placebo Comparator | 12.2 |
percentage of participants who reported suicidal ideation during treatment but not at baseline (NCT00892047)
Timeframe: 12 weeks
| Intervention | percent of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 21.3 |
| 2: Placebo Comparator | 29.2 |
Percentage of participants who develop signs of parkinsonism (NCT00892047)
Timeframe: 12weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 17.4 |
| 2: Placebo Comparator | 2.5 |
The Montgomery-Asberg Depression Rating Scale (MADRS) is a clinician rated ten item instrument assessing depression symptoms. Possible scores range from 0-60; higher scores indicate greater severity of depression. Remission defined as score of 10 or less based on the MADRS. (NCT00892047)
Timeframe: 12 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 44 |
| 2: Placebo Comparator | 29 |
percentage of participants (NCT00892047)
Timeframe: 12 weeks
| Intervention | percent of participants (Number) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 1.3 |
| 2: Placebo Comparator | 0 |
Weight change in kilograms (NCT00892047)
Timeframe: Baseline through12 weeks
| Intervention | kilograms (Mean) |
|---|---|
| 1: Venlafaxine Plus Aripiprazole | 1.93 |
| 2: Placebo Comparator | 0.01 |
Cumulative incident response of anxiety symptom improvement on CGI-I, with 1 (very much improved) to 2 (much improved) indicated as response. Scores synthesized from anxiety rating scale scores, including Penn State Worry Questionnaire (PSWQ) and Hamilton Anxiety Scale (HamA). (NCT00105586)
Timeframe: Measured at Weeks 1-12
| Intervention | participants (Number) |
|---|---|
| Placebo | 51 |
| Escitalopram | 69 |
Role -emotional impairment score from the Late-Life Function and Disability Instrument (min score=0, significant impairment; max score=100, no impairment). (NCT00105586)
Timeframe: Measured at Week 12
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Week 0 SF-36 Role-Emotional Impairment | Week 12 SF-36 Role-Emotional Impairment | |
| Escitalopram (1) | 42.19 | 62.50 |
| Placebo (2) | 53.42 | 56.16 |
The Hamilton Anxiety Rating Scale is a clinician-rated measure of cognitive and somatic anxiety symptoms. It consists of 14 items, each of which is scored on a 0-4 scale, summed for a total score ranging from 0 to 56. Inclusion criteria for this study included a Hamilton score >= 17. The Hamilton, administered by blind raters, will be used to test hypotheses number 1 and 2. The outcome of interest is the number of participants who relapse, defined as having a Hamilton increase of >=5, for a total Hamilton >=14, relative to the end of the continuation phase (week 28), for a duration of at least 2 weeks, plus both clinician's and participant's judgment that the participant is experiencing a recurrence of anxiety symptoms. HAMA scores range from 0 (no anxiety) to 56 (high anxiety). (NCT00601965)
Timeframe: 56 weeks
| Intervention | participants (Number) |
|---|---|
| Escitalopram + CBT | 18 |
| Escitalopram + no CBT | 15 |
| Placebo + CBT | 14 |
| Placebo + no CBT | 8 |
The Penn State Worry Questionnaire is a 16-item measure of pathological worry. Scores range from 16-80, with higher scores indicating higher levels of worry. (NCT00601965)
Timeframe: 56 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + CBT | 52.8 |
| Escitalopram + no CBT | 53.4 |
| Placebo + CBT | 54.4 |
| Placebo + no CBT | 57.7 |
"Change in RMDQ from randomization to 14 weeks. The Roland-Morris is a 24-item self-report questionnaire about how low-back pain affects functional activities. Each question is worth one point so scores can range from 0 (no disability) to 24 (severe disability).~Improvement of 30% is clinically meaningful" (NCT01124188)
Timeframe: Baseline and 14 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Study Intervention Arm | -3.67 |
| Active Control | -3.20 |
"Change in SPPB scores from randomization to 14 weeks for both arms.~The Short Physical Performance Battery (SPPB) assesses physical performance. The SPPB scores range from 0-12 and assess lower extremity strength, balance, and gait speed, three meaningful predictors of morbidity and mortality in late-life. Lower scores on the SPPB indicates greater limitations. Improvement of 0.5 points indicate clinically meaningful improvement in physical performance" (NCT01124188)
Timeframe: Baseline and 14 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Study Intervention Arm | 0.49 |
| Active Control | 0.54 |
The PHQ-9 depression questionnaire scores range from 0 to 27. The higher the score the more severe the depression. A PHQ-9 score less than or equal to 5 represents absence of depression. The Numeric Rating scale is a self report pain scale ranging from 0 to 20. Higher numbers indicate more pain. Response in this study was defined as two consecutive PHQ-9 scores < or = to 5 AND Numeric Rating Scale for pain (NRS) > or = 30% reduction from study entry. (NCT01124188)
Timeframe: 14 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Study Intervention Arm | 28 |
| Active Control | 28 |
total score ranges from 0 (not depressed) to 63 (most severe) (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 10.7 |
7 point scale of overall severity of psychopathology from 1 mildest to 7 most severe. (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 1.4 |
measures severity of symptoms of generalized anxiety disorder, reported as a total score summing 10 items that are each rated from 0, never to 4, all of the time. Range is 0 to 40, with 40 most severe. (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 4.8 |
The Hamilton Anxiety Rating Scale is a clinician administered rating scale assessing severity of anxiety from 0 (low) to 64 (high). The greater the magnitude of decrease in score during treatment, the greater the improvement in anxiety. (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | -6.4 |
24 item version of this standard depression scale, total score ranges from 0 (not depressed) to 58 (most severe) (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 7.3 |
total score (of 16 items) ranging from 16 (least worry) to 80 (most worry) (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 9.8 |
only the total score of the state anxiey subscale was used. Range is from 20 (mildest) to 80 (most severe) (NCT00219349)
Timeframe: week 14 to week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 15.4 |
This is a single item rating overall symptomatic improvement. Range is 0 (very much worse) to 7 (very much improved) (NCT00219349)
Timeframe: week 26
| Intervention | units on a scale (Mean) |
|---|---|
| Patients Who Started Escitalopram | 3.0 |
Change from baseline: average across visit weeks using mixed model. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, & restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety. (NCT00413010)
Timeframe: Baseline, 8 weeks
| Intervention | score on scale (Least Squares Mean) |
|---|---|
| Pregabalin | -7.6 |
| Placebo | -6.4 |
Time to sustained improvement was defined as time to 50% or greater reduction in HAM-A total score from Baseline, which was sustained for the remainder of the study. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; a higher score indicates greater anxiety. (NCT00413010)
Timeframe: Week 8
| Intervention | days (Median) |
|---|---|
| Pregabalin | 57 |
Change: score at each study week minus score at baseline. HAM-A, a clinician-rated interview, measures presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, & restlessness. Total score ranges from 0 to 56; higher score indicates greater anxiety. (NCT00413010)
Timeframe: Baseline, Weeks 1 through Week 8
| Intervention | score on scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 (n=164;n=169) | Week 2 (n=166;n=163) | Week 3 (n=157;n=160) | Week 4 (n=153;n=150) | Week 5 (n=135;n=130) | Week 6 (n=122;n=125) | Week 8 (n=126;n=127) | |
| Placebo | -3.1 | -5.2 | -5.5 | -7.0 | -7.6 | -8.0 | -8.0 |
| Pregabalin | -4.4 | -6.3 | -7.0 | -8.3 | -8.4 | -9.2 | -9.3 |
Change: score at each study week minus score at baseline. HAM-D, clinician-rated interview, measures presence of depressive symptoms in 17 areas (symptoms such as depressed mood, guilty feelings, suicide, sleep disturbances, anxiety levels, & weight loss). Total score ranges from 0 to 52; higher scores indicate more depression. (NCT00413010)
Timeframe: Weeks 1 through Week 8
| Intervention | score on scale (Least Squares Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 n=165,168 | Week 2 n=165,164 | Week 3 n=156,160 | Week 4 n=153, 149 | Week 5 n=135, 130 | Week 6 n=122, 125 | Week 8 n= 126, 127 | |
| Placebo | -1.3 | -2.4 | -2.8 | -3.3 | -3.9 | -3.8 | -3.8 |
| Pregabalin | -2.1 | -3.1 | -3.5 | -4.7 | -4.3 | -4.7 | -4.8 |
CGI-S is a clinician-rated instrument measuring the severity of a subject's symptoms on a 7-point categorical scale. Scores range from 1 (not at all ill) to 7 (among the most extremely ill patients). Higher score indicates that the subject is more ill. (NCT00413010)
Timeframe: Week 8
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Normal, not ill at all | Borderline, mentally ill | Mildly ill | Moderately ill | Markedly ill | Severely ill | Among the most extremely ill | Not assessed | |
| Placebo | 18 | 37 | 63 | 48 | 8 | 1 | 0 | 1 |
| Pregabalin | 28 | 49 | 49 | 46 | 2 | 2 | 0 | 0 |
Responders = YES using CGI-I if score indicated much improved or very much improved at the last study week. CGI-I is a clinician-rated instrument that measures change in subject's overall status on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). (NCT00413010)
Timeframe: Week 1 through Week 8
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1: Yes | Week 1: No | Week 2: Yes | Week 2: No | Week 3: Yes | Week 3: No | Week 4: Yes | Week 4: No | Week 5: Yes | Week 5: No | Week 6: Yes | Week 6: No | Week 8: Yes | Week 8: No | Week 8 (LOCF): Yes | Week 8 (LOCF): No | |
| Placebo | 49 | 120 | 74 | 89 | 76 | 86 | 88 | 61 | 81 | 50 | 76 | 49 | 82 | 45 | 110 | 66 |
| Pregabalin | 62 | 101 | 94 | 72 | 93 | 62 | 97 | 55 | 89 | 45 | 83 | 38 | 80 | 43 | 113 | 61 |
Responders = YES if subjects achieved a >= 50% decrease in HAM-A total score from Baseline to respective study week. HAM-A is a clinician-rated interview measuring the presence of anxiety-related symptoms in 14 areas. Total score ranges from 0 to 56; higher score indicates greater anxiety. (NCT00413010)
Timeframe: Weeks 1 through Week 8
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 Responder: Yes | Week 1 Responder: No | Week 2 Responder: Yes | Week 2 Responder: No | Week 3 Responder: Yes | Week 3 Responder: No | Week 4 Responder: Yes | Week 4 Responder: No | Week 5 Responder: Yes | Week 5 Responder: No | Week 6 Responder: Yes | Week 6 Responder: No | Week 8 Responder: Yes | Week 8 Responder: No | Week 8 (LOCF) Responder: Yes | Week 8 (LOCF) Responder: No | |
| Placebo | 8 | 161 | 26 | 137 | 23 | 137 | 46 | 104 | 46 | 84 | 48 | 77 | 47 | 80 | 62 | 114 |
| Pregabalin | 21 | 143 | 39 | 127 | 51 | 106 | 64 | 89 | 58 | 77 | 57 | 65 | 63 | 63 | 84 | 93 |
Participant in remission defined as HAM-A total score of <= 7. HAM-A=clinician-rated interview measuring presence of anxiety-related symptoms in 14 areas including anxiety, tension, depressed mood, palpitations, breathing difficulties, sleep disturbances, & restlessness. Total score ranges 0 - 56; higher score indicates greater anxiety. (NCT00413010)
Timeframe: Week 1 through Week 8
| Intervention | participants (Number) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 1 Remission: Yes | Week 1 Remission: No | Week 2 Remission: Yes | Week 2 Remission: No | Week 3 Remission: Yes | Week 3 Remission: No | Week 4 Remission: Yes | Week 4 Remission: No | Week 5 Remission: Yes | Week 5 Remission: No | Week 6 Remission: Yes | Week 6 Remission: No | Week 8 Remission: Yes | Week 8 Remission: No | Week 8 (LOCF) Remission: Yes | Week 8 (LOCF) Remission: No | |
| Placebo | 5 | 164 | 15 | 148 | 18 | 142 | 29 | 121 | 30 | 100 | 32 | 93 | 31 | 96 | 42 | 134 |
| Pregabalin | 12 | 152 | 22 | 144 | 32 | 125 | 43 | 110 | 39 | 96 | 37 | 85 | 40 | 86 | 55 | 122 |
The API is a well-validated and reliable measure of abdominal pain assessing the frequency, duration, and intensity of abdominal pain consisting of five items assessing the frequency, duration, and intensity of abdominal pain experienced during the prior 2 weeks. Two of the items are scored from 0 to 5, one is scaled 0 to 8, and two are scaled 0 to 10, with lower scores considered to be better than higher scores. Item scores are standardized using Z-scores and then summed to yield an index of abdominal pain that has been sensitive to change in previous epidemiological and treatment studies of FAP. Alpha reliability ranged from 0.80 to 0.93. The API will be a continuous primary outcome measure of abdominal pain. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| API-C Week 0 | API-C Week 2 | API-C Week 4 | API-C Week 8 | |
| Citalopram | 0.45 | -0.14 | -0.21 | -0.36 |
| Placebo | 0.47 | 0.06 | 0.08 | -0.03 |
Children's Depression Rating Scale - Revised (CDRS-R) is a clinician administered measure of depression in children and adolescents and provides data necessary to diagnose depressive disorder and rate the severity of depressive symptoms over time. The CDRS-R is composed of 17 items, most rated on a 1 to 7 scale, with a minimum score of 17 and a maximum of 113. Higher scores reflect greater depression severity, with scores of 40 and above generally considered to be reflective of a depressive diagnosis. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| CDRS-R Week 0 | CDRS-R Week 2 | CDRS-R Week 4 | CDRS-R Week 8 | |
| Citalopram | 34.50 | 27.81 | 24.97 | 23.88 |
| Placebo | 39.23 | 31.89 | 28.35 | 28.39 |
Children's Global Assessment Scale (C-GAS) is an interview-based adaptation of the Global Assessment Scale developed to assess child and adolescent functioning during a specified time period. Scores range from one to 100, with scores of 70 or below reflecting abnormally low functioning and higher scores reflecting better functioning. The C-GAS has demonstrated reliability, as well as discriminant and concurrent validity. A CGAS score of < 70 will be a requirement at study entry. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| CGAS Week 0 | CGAS Week 2 | CGAS Week 4 | CGAS Week 8 | |
| Citalopram | 54.42 | 59.24 | 63.27 | 66.72 |
| Placebo | 54.07 | 58.05 | 59.14 | 61.22 |
Clinical Global Impression Scale - Improvement (CGI-I) is a 7-point scale, with lower values being more favorable, used to assess overall global illness improvement. The CGI is a clinician-completed measure, with values ranging from 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse), 6 (much worse), to 7 (very much worse). CGI-I scores of 1 (very much improved) or 2 (much improved) were considered to indicate an acceptable treatment response. A global measure of functional status was chosen as a primary outcome due to the broad array of symptomatology seen in pediatric RAP and the ambiguous relationship between functional status and symptoms of pain, anxiety, and depression in pediatric RAP. The CGI-I is a dichotomous primary outcome measure of global clinical improvement with clinical response be defined as a CGI-I score of 1 or 2 for at least two consecutive weeks. (NCT00962039)
Timeframe: The CGI will be completed at weeks 2, 4, and 8
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| CGI-I Week 2 | CGI-I Week 4 | CGI-I Week 8 | |
| Citalopram | 3.48 | 3.03 | 2.65 |
| Placebo | 3.68 | 3.38 | 3.24 |
Clinical Global Impression Scale - Severity (CGI-S) is a 7-point scale is a clinician-completed measure that requires the clinician to rate the severity of the patient's illness at the time of assessment relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of illness at the time of rating, with values ranging from 1 (normal, not at all ill), 2 (borderline ill), 3 (mildly ill), 4 (moderately ill), 5 (markedly ill), 6 (severely ill), to 7 (extremely ill). (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| CGI-S Week 0 | CGI-S Week 2 | CGI-S Week 4 | CGI-S Week 8 | |
| Citalopram | 4.31 | 3.83 | 3.56 | 2.76 |
| Placebo | 4.39 | 4.03 | 3.86 | 3.51 |
Pediatric Anxiety Rating Scale (PARS) is a clinician administered measure of anxiety in children and adolescents. The PARS is comprised of a 50-item symptom checklist used to determine the presence or absence of specific anxiety symptoms during the prior week and 7 severity/impairment items, each scored from 0 to 5 . The the score on the 7 items allows the clinician to rate symptom severity and associated impairment on a range from 0 to 35, with higher scores reflecting greater symptom severity and associated impairment. The PARS is characterized by high interrater reliability (ICC = 0.97), adequate internal consistency (α = 0.64), and fair test-retest reliability (ICC = 0.55). There is preliminary support for convergent and divergent validity, and the PARS has demonstrated sensitivity to treatment effects in previously conducted clinical trials. (NCT00962039)
Timeframe: Weeks 0, 2, 4, and 8
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| PARS Week 0 | PARS Week 2 | PARS Week 4 | PARS Week 8 | |
| Citalopram | 7.38 | 4.00 | 2.57 | 2.69 |
| Placebo | 9.73 | 6.78 | 5.76 | 5.55 |
30 reviews available for citalopram and Anxiety Neuroses
| Article | Year |
|---|---|
Selective Serotonin Reuptake Inhibitor Monotherapy for Anxiety Disorders in Children and Adolescents with Autism Spectrum Disorder: A Chart Review.
Topics: Adolescent; Anxiety Disorders; Autism Spectrum Disorder; Citalopram; Comorbidity; Female; Fluoxetine | 2019 |
Antidepressants for anxiety disorders in late-life: A systematic review.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Duloxetine Hydrochloride; Humans; Late O | 2019 |
Interventions for comorbid problem gambling and psychiatric disorders: Advancing a developing field of research.
Topics: Acetylcysteine; Antimanic Agents; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Bipolar | 2016 |
[Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Topics: Anxiety Disorders; Citalopram; Diagnosis, Differential; Humans; Obsessive-Compulsive Disorder; Panic | 2008 |
How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder, Major; | 2009 |
Refractory generalized anxiety disorder.
Topics: Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Anxiet | 2009 |
Generalised anxiety disorder.
Topics: Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Double-Blind Method; Humans; Paroxetine | 2007 |
Update on partial response in depression.
Topics: Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Chronic Disease; Citalopram; Comorbi | 2009 |
Effects of escitalopram on sleep problems in patients with major depression or generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; | 2011 |
Escitalopram.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Humans | 2002 |
Escitalopram: efficacy and tolerability in the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Humans | 2002 |
Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials as | 2003 |
Escitalopram and suicidality in adult depression and anxiety.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Databases, Factual; Depress | 2005 |
Escitalopram: better treatment for depression is through the looking glass.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials as Topic; D | 2004 |
Somatic symptoms in late-life anxiety: treatment issues.
Topics: Age of Onset; Aged; Anxiety Disorders; Citalopram; Female; Health Status; Humans; Male; Middle Aged; | 2005 |
Escitalopram in the treatment of generalized anxiety disorder.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Humans | 2005 |
Discontinuation symptoms in depression and anxiety disorders.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depre | 2007 |
Managing depressive and anxiety disorders with escitalopram.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive D | 2006 |
Mood, anxiety, and physical illness: body and mind, or mind and body?
Topics: Anxiety Disorders; Autoimmune Diseases; Citalopram; Comorbidity; Health Status; Heart Diseases; Huma | 2006 |
Escitalopram: a review of its use in the management of anxiety disorders.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Humans; MEDLINE | 2006 |
What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Ment | 2006 |
Citalopram and suicidality in adult major depression and anxiety disorders.
Topics: Adverse Drug Reaction Reporting Systems; Antidepressive Agents, Second-Generation; Anxiety Disorders | 2006 |
Which factors predict placebo response in anxiety disorders and major depression? An analysis of placebo-controlled studies of escitalopram.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Hum | 2006 |
The clinical pharmacokinetics of escitalopram.
Topics: Adolescent; Adult; Age Factors; Aged; Anxiety Disorders; Child; Citalopram; Depression; Drug Interac | 2007 |
Escitalopram therapy for major depression and anxiety disorders.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Depressive Disorder, Majo | 2007 |
The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Biological Availability; Citalopram; De | 2007 |
Qualitative changes in symptomatology as an effect of treatment with escitalopram in generalized anxiety disorder and major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Databases, Factual; Depress | 2008 |
Anxious depression and response to treatment.
Topics: Anxiety Disorders; Citalopram; Comorbidity; Depressive Disorder; Humans; Meta-Analysis as Topic; Psy | 2008 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Care of depressed patients with anxiety symptoms.
Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Citalopram; Clinical Trials as Topic; Comorbidi | 1999 |
Citalopram: a comprehensive review.
Topics: Alcoholism; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Clinical Trials | 2001 |
78 trials available for citalopram and Anxiety Neuroses
| Article | Year |
|---|---|
Maintenance or Discontinuation of Antidepressants in Primary Care.
Topics: Adult; Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive Disorder; Double-Blind | 2021 |
Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors.
Topics: Adolescent; Anxiety; Anxiety Disorders; Autism Spectrum Disorder; Child; Citalopram; Humans; Selecti | 2022 |
A Multicenter Double-Blind, Placebo-Controlled Trial of Escitalopram in Children and Adolescents with Generalized Anxiety Disorder.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Double-Blind Method; Escitalopram; Humans; Nucleot | 2023 |
Treatment for anxiety: Mindfulness meditation versus escitalopram (TAME): Design of a randomized, controlled non-inferiority trial.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Citalopram; Equivalence Trials as Topic; Female; Humans; | 2020 |
Escitalopram in Adolescents With Generalized Anxiety Disorder: A Double-Blind, Randomized, Placebo-Controlled Study.
Topics: Adolescent; Anti-Anxiety Agents; Anxiety Disorders; Area Under Curve; Child; Citalopram; Cytochrome | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Coprescribed Benzodiazepines in Older Adults Receiving Antidepressants for Anxiety and Depressive Disorders: Association With Treatment Outcomes.
Topics: Aged; Aged, 80 and over; Aging; Antidepressive Agents, Second-Generation; Anxiety Disorders; Benzodi | 2020 |
Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.
Topics: Adolescent; Amygdala; Anxiety; Anxiety Disorders; Child; Citalopram; Double-Blind Method; Female; Hu | 2021 |
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Topics: Acetamides; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Female; Fol | 2018 |
Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized Anxiety Disorder and Unipolar Major Depression With an Early Nonresponse to Escitalopram: A Double-Blind Placebo-Controlled Study.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; | 2019 |
Paradoxical effects of short-term antidepressant treatment in fMRI emotional processing models in volunteers with high neuroticism.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Discrimination, Psychological; Double-B | 2014 |
Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults.
Topics: Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cognitive Behavioral | 2013 |
Common selective serotonin reuptake inhibitor side effects in older adults associated with genetic polymorphisms in the serotonin transporter and receptors: data from a randomized controlled trial.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Genotype; H | 2014 |
Prevention of post-stroke generalized anxiety disorder, using escitalopram or problem-solving therapy.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cognitive Beha | 2014 |
Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study.
Topics: Acetamides; Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Double-Blin | 2014 |
Prognostic subgroups for citalopram response in the STAR*D trial.
Topics: Adult; Aged; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Educational Status; Female; | 2014 |
Emotion reactivity and regulation in late-life generalized anxiety disorder: functional connectivity at baseline and post-treatment.
Topics: Aged; Aging; Anxiety Disorders; Brain Mapping; Case-Control Studies; Cerebral Cortex; Citalopram; Em | 2015 |
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial.
Topics: Aged; Anxiety Disorders; Apathy; Citalopram; Cognition Disorders; Depressive Disorder, Major; Double | 2015 |
Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.
Topics: Antidepressive Agents; Anxiety Disorders; Citalopram; Cognition; Depressive Disorder, Major; Female; | 2015 |
The association between latent depression subtypes and remission after treatment with citalopram: A latent class analysis with distal outcome.
Topics: Adult; Anxiety Disorders; Bulimia; Citalopram; Depression; Feeding and Eating Disorders; Female; Hum | 2015 |
Emotional Reactivity and Regulation Following Citalopram Therapy in Children and Adolescents with Anxiety Disorders.
Topics: Adolescent; Affective Symptoms; Anxiety Disorders; Child; Citalopram; Female; Follow-Up Studies; Hum | 2017 |
Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial.
Topics: Adult; Aged; Anxiety Disorders; Biomarkers; Citalopram; Cognitive Behavioral Therapy; Female; Humans | 2016 |
Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Depressive Disorder, Major; Dysthymic Disorder; Fe | 2016 |
Combining escitalopram and cognitive-behavioural therapy for social anxiety disorder: randomised controlled fMRI trial.
Topics: Adult; Amygdala; Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Combined Modality Ther | 2016 |
Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive Disorder, | 2008 |
Analysis of health-related quality of life and costs based on a randomised clinical trial of escitalopram for relapse prevention in patients with generalised social anxiety disorder.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Cost-Benefit Analysis; Drug Costs; Humans; Quali | 2008 |
Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Female; Humans; Male; Middle Aged; Psychiatr | 2009 |
A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers.
Topics: Acoustic Stimulation; Adult; Anxiety Disorders; Blood Pressure; Citalopram; Cross-Over Studies; Doub | 2010 |
Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder.
Topics: Adult; Anxiety Disorders; Citalopram; Delayed-Action Preparations; Double-Blind Method; Drug Therapy | 2009 |
Tryptophan depletion affects the autonomic stress response in generalized social anxiety disorder.
Topics: Anxiety Disorders; Autonomic Nervous System; Citalopram; Female; Humans; Hydrocortisone; Male; Saliv | 2009 |
Use of the late-life function and disability instrument to assess disability in major depression.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxie | 2009 |
Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study.
Topics: Adolescent; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; | 2010 |
Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anxiety Disorders; Citalopram; Depressive Disorder; Dou | 2010 |
Anxiety impairs depression remission in partial responders during extended treatment in late-life.
Topics: Age Factors; Aged; Anxiety Disorders; Citalopram; Combined Modality Therapy; Depressive Disorder, Ma | 2010 |
Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Diagnostic and Statisti | 2010 |
Escitalopram for persistent symptoms of generalized anxiety disorder after CBT: a pilot study.
Topics: Adolescent; Adult; Aged; Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Combined Modal | 2010 |
Neuroticism but not omega-3 fatty acid levels correlate with early responsiveness to escitalopram.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Character; Citalopram; Depressiv | 2010 |
Elevated cortisol in older adults with generalized anxiety disorder is reduced by treatment: a placebo-controlled evaluation of escitalopram.
Topics: Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Female; Genotype; Humans; Hydrocortisone; Hy | 2011 |
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Depress | 2010 |
Relation of serotonin transporter genetic variation to efficacy of escitalopram for generalized anxiety disorder in older adults.
Topics: Age Factors; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Female; Genotype; Haplotypes; H | 2010 |
An open, non-randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder.
Topics: Adolescent; Adrenergic Uptake Inhibitors; Adult; Analysis of Variance; Anxiety Disorders; Citalopram | 2011 |
Treatment-emergent suicidal ideation during 4 months of acute management of unipolar major depression with SSRI pharmacotherapy or interpersonal psychotherapy in a randomized clinical trial.
Topics: Adult; Anxiety Disorders; Benzodiazepines; Citalopram; Combined Modality Therapy; Comorbidity; Depre | 2011 |
Melancholic, atypical and anxious depression subtypes and outcome of treatment with escitalopram and nortriptyline.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 2011 |
Treatment-related alteration of cortisol predicts change in neuropsychological function during acute treatment of late-life anxiety disorder.
Topics: Aged; Aged, 80 and over; Anxiety Disorders; Biomarkers; Citalopram; Double-Blind Method; Executive F | 2012 |
Changes in neuropsychological functioning following treatment for late-life generalised anxiety disorder.
Topics: Adult; Age Factors; Aged; Anxiety Disorders; Attention; Citalopram; Cognition Disorders; Disability | 2011 |
Using an experimental medicine model to explore combination effects of pharmacological and cognitive interventions for depression and anxiety.
Topics: Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive D | 2011 |
Randomised clinical trial: escitalopram for the prevention of psychiatric adverse events during treatment with peginterferon-alfa-2a and ribavirin for chronic hepatitis C.
Topics: Adult; Antiviral Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Therapy, Combinati | 2011 |
Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment.
Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Cyclohexa | 2012 |
Citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2012 |
Citalopram treatment of paroxetine-intolerant depressed patients.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Drug Tolerance; Female; Humans; Ma | 2002 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Increased positive versus negative affective perception and memory in healthy volunteers following selective serotonin and norepinephrine reuptake inhibition.
Topics: Adrenergic Uptake Inhibitors; Adult; Affect; Anger; Anxiety Disorders; Citalopram; Cognition; Depres | 2004 |
Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Diagnostic and Statistica | 2004 |
Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study.
Topics: Abdominal Pain; Adolescent; Anxiety Disorders; Child; Citalopram; Comorbidity; Depression; Female; H | 2004 |
Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial.
Topics: Age Factors; Aged; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Humans; Male; Placebo | 2005 |
Somatic symptoms in late-life anxiety: treatment issues.
Topics: Age of Onset; Aged; Anxiety Disorders; Citalopram; Female; Health Status; Humans; Male; Middle Aged; | 2005 |
Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Demography; Dose-Response | 2005 |
Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
Topics: Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Dose- | 2006 |
The effect of pharmacotherapy on personality disorders in panic disorder: a one year naturalistic study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Female; | 2005 |
Prevention of relapse in generalized anxiety disorder by escitalopram treatment.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Dis | 2006 |
Antidepressant treatment outcomes of psychogenic movement disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Combined Modality Therapy; C | 2005 |
Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder.
Topics: Adult; Ambulatory Care; Anxiety Disorders; Chronic Disease; Citalopram; Diagnostic and Statistical M | 2005 |
Outcomes of late-life anxiety disorders during 32 weeks of citalopram treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Ge | 2006 |
Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Gambling; | 2006 |
Escitalopram in the treatment of anxiety symptoms associated with depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Depress | 2007 |
Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study.
Topics: Adult; Aged; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Humans; Male; Middle Aged; | 2006 |
A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety Disord | 2007 |
Escitalopram for comorbid depression and anxiety in elderly patients: A 12-week, open-label, flexible-dose, pilot trial.
Topics: Aged; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Pilot Project | 2006 |
Bupropion in the treatment of outpatients with asthma and major depressive disorder.
Topics: Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiety Disorders; Asthma; Bupropion; Cit | 2007 |
Health-related quality of life (HRQOL) among patients with Generalised Anxiety Disorder: evaluation conducted alongside an escitalopram relapse prevention trial.
Topics: Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Double-Blind Method; Female; Humans; Male; Place | 2007 |
Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Delay | 2008 |
Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Anxiety Disorders; Citalopram; Como | 2008 |
Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Citalopram; Depressi | 2007 |
A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Bupropion; Citalopram; Double-Bl | 2008 |
Eszopiclone coadministered with escitalopram in patients with insomnia and comorbid generalized anxiety disorder.
Topics: Adolescent; Adult; Anxiety Disorders; Azabicyclo Compounds; Citalopram; Comorbidity; Diagnostic and | 2008 |
Selective serotonin re-uptake inhibitors (SSRIs) and alopecia areata.
Topics: Adult; Alopecia Areata; Anxiety Disorders; Citalopram; Depression; Female; Humans; Middle Aged; Psyc | 1999 |
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders | 1999 |
Treatment of generalized anxiety disorder with citalopram.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anxiety Disorders; Citalopram; Depression; Drug Resistan | 2002 |
Combined psychoeducation and treatment with selective serotonin reuptake inhibitors for youth with generalized social anxiety disorder.
Topics: Adolescent; Age Factors; Anxiety Disorders; Child; Citalopram; Combined Modality Therapy; Female; Hu | 2002 |
81 other studies available for citalopram and Anxiety Neuroses
| Article | Year |
|---|---|
[Effect of the direct healthcare professional communication on citalopram and escitalopram drug utilization for inpatient treatment of anxiety disorders].
Topics: Anxiety Disorders; Citalopram; Communication; Delivery of Health Care; Drug Utilization; Escitalopra | 2022 |
Neuroimaging, genetic, clinical, and demographic predictors of treatment response in patients with social anxiety disorder.
Topics: Adult; Amygdala; Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Demography; Female; Gy | 2020 |
The influence of age-of-onset of antidepressant use on the acute CBF response to a citalopram challenge; a pharmacological MRI study.
Topics: Adult; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cerebrovascular Cir | 2020 |
Dilated pupils in an anxious patient.
Topics: Alprazolam; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalo | 2021 |
Higher baseline serum adiponectin predicts better treatment remission in patients with generalized anxiety disorder treated with escitalopram.
Topics: Adiponectin; Anxiety Disorders; Citalopram; Humans; Treatment Outcome; Venlafaxine Hydrochloride | 2021 |
Effects of Selective Seratonine Re-Uptake Inhibitors on Meniere's Disease.
Topics: Acetazolamide; Adult; Anxiety Disorders; Betahistine; Citalopram; Diuretics; Female; Humans; Male; M | 2017 |
"Dhat syndrome" - How a man lost his bones!
Topics: Adolescent; Anxiety Disorders; Bibliotherapy; Citalopram; Humans; Male; Selective Serotonin Reuptake | 2017 |
Biphasic effects of selective serotonin reuptake inhibitors on anxiety: rapid reversal of escitalopram's anxiogenic effects in the novelty-induced hypophagia test in mice?
Topics: Animals; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; Behavior, Animal; C | 2018 |
Early improvement predicts 8-week treatment outcome in patients with generalized anxiety disorder treated with escitalopram or venlafaxine.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Female; Humans; Male | 2017 |
Changes in miRNA-132 and miR-124 levels in non-treated and citalopram-treated patients with depression.
Topics: Adult; Anxiety Disorders; Brain-Derived Neurotrophic Factor; Case-Control Studies; Citalopram; Corre | 2018 |
Escitalopram-induced delayed drug rash with deranged liver function: a possible case of drug reaction with eosinophilia and systemic reaction.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Drug Eruptions; Eosi | 2018 |
Escitalopram in the Treatment of Anxiety in Chromosome 18p Deletion.
Topics: Adolescent; Anxiety Disorders; Chromosome Deletion; Chromosomes, Human, Pair 18; Citalopram; Female; | 2018 |
Association of NPSR1 rs324981 polymorphism and treatment response to antidepressants in Chinese Han population with generalized anxiety disorder.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; China; Citalopram; Female; Gene F | 2018 |
Antidepressant Prescription Patterns in Bipolar Disorder: a Nationwide, Register-based Study in Korea.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Anxiety Disor | 2018 |
The roles of brain-derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor (GDNF) in predicting treatment remission in a Chinese Han population with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Brain-Derived Neurotrophic Factor; China; Citalopram; | 2019 |
Neuroticism predicts the impact of serotonin challenges on fear processing in subgenual anterior cingulate cortex.
Topics: Adult; Anger; Anxiety Disorders; Citalopram; Emotions; Facial Expression; Fear; Female; Humans; Magn | 2018 |
Escitalopram related edema in a patient with Hashimoto's thyroiditis.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Depression; Edema; Female; Hashimoto Di | 2019 |
Effects of SSRIs on peripheral inflammatory cytokines in patients with Generalized Anxiety Disorder.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Anxiety Disorders; C-Reactive Prot | 2019 |
Ondansetron-Induced Myoclonus With Escitalopram and HAART: Role of Drug Interactions.
Topics: Adult; Anti-Anxiety Agents; Antiretroviral Therapy, Highly Active; Anxiety Disorders; Citalopram; Dr | 2019 |
Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders.
Topics: Adolescent; Anxiety Disorders; Child; Citalopram; Depressive Disorder; Female; Humans; Male; Polymor | 2013 |
The effect of escitalopram on metabolic parameters in patients with major depressive disorder, generalised anxiety disorder, and panic disorder: a prospective 6-month follow-up study.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; | 2013 |
What are the optimal treatment courses for geriatric anxiety, and how do we find out?
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cognitive Behavioral Therap | 2013 |
[Hallucinogen persisting perception disorder after ecstasy use].
Topics: Anxiety Disorders; Citalopram; Depressive Disorder; Hallucinations; Hallucinogens; Humans; Male; N-M | 2013 |
Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy.
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Attention; Case-Control Studies; Citalopram; Cycloh | 2013 |
Effective combination treatment for generalized anxiety disorder. Two-pronged treatment with medication and cognitive behavior therapy enables renewed function and worry reduction.
Topics: Adult; Age Factors; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy | 2013 |
Treatment with citalopram, but not with agomelatine, adversely affects sperm parameters: a case report and translational review.
Topics: Acetamides; Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressi | 2014 |
Euprolactinemic galactorrhea with escitalopram.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Female; Galactorrhea; Human | 2014 |
Perinatal vs genetic programming of serotonin states associated with anxiety.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain; Citalopram; Disease Mod | 2015 |
Demolition Site: Rhinotillexomania.
Topics: Aged, 80 and over; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Disruptive, Impulse Control, | 2016 |
Functional Impairment and Changes in Depression Subtypes for Women in STAR*D: A Latent Transition Analysis.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depression; Fe | 2016 |
Mental Stress-Induced Myocardial Ischemia Related to Generalized Anxiety Disorder in a Patient With Acute Coronary Syndrome and Normal Coronary Arteries.
Topics: Acute Coronary Syndrome; Anxiety Disorders; Citalopram; Computed Tomography Angiography; Coronary An | 2016 |
Eyelash Loss Secondary to Escitalopram But Not to Sertraline: A Case Report.
Topics: Adult; Alopecia; Anxiety Disorders; Citalopram; Female; Humans; Mood Disorders; Selective Serotonin | 2016 |
Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment.
Topics: Animals; Anxiety; Anxiety Disorders; Behavior, Animal; Black or African American; Brain-Derived Neur | 2017 |
Citalopram-induced dyskinesia of the tongue: a video presentation.
Topics: Anxiety Disorders; Citalopram; Dyskinesia, Drug-Induced; Humans; Male; Middle Aged; Remission, Spont | 2016 |
SK3 K+ channel-deficient mice have enhanced dopamine and serotonin release and altered emotional behaviors.
Topics: Animals; Anti-Bacterial Agents; Anxiety Disorders; Behavior, Animal; Brain; Citalopram; Dopamine; Do | 2008 |
Family history of depression and therapeutic outcome: findings from STAR*D.
Topics: Adult; Age Factors; Alcoholism; Antidepressive Agents; Anxiety Disorders; Citalopram; Comorbidity; C | 2009 |
[Chorea during treatment with pegylated interferon and ribavirin in HIV-HCV coinfected patient].
Topics: Adult; Anti-HIV Agents; Antidepressive Agents; Antiviral Agents; Anxiety Disorders; Chorea; Citalopr | 2009 |
Early adversity in chronic depression: clinical correlates and response to pharmacotherapy.
Topics: Adolescent; Adult; Age of Onset; Aged; Algorithms; Antidepressive Agents; Anxiety Disorders; Bupropi | 2009 |
Escitalopram treatment of generalized anxiety disorder in older adults.
Topics: Aged; Anxiety Disorders; Citalopram; Humans; Selective Serotonin Reuptake Inhibitors | 2009 |
Depression-like and anxiety-like behavioural aftermaths of impact accelerated traumatic brain injury in rats: a model of comorbid depression and anxiety?
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety Disorders; Brain Injuries; Citalopram; Co | 2009 |
Acute maniform reaction to a single dose of escitalopram in a social phobic patient--an atypical jitteriness syndrome?
Topics: Akathisia, Drug-Induced; Anxiety Disorders; Citalopram; Humans; Male; Mood Disorders; Phobic Disorde | 2009 |
Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder.
Topics: Activities of Daily Living; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; | 2010 |
Affective and anxiety disorders: prevalence, treatment and antidepressant medication use.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; A | 2010 |
Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study.
Topics: Aged; Aged, 80 and over; Anxiety Disorders; Behavior Therapy; Citalopram; Cognitive Behavioral Thera | 2011 |
Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders.
Topics: Adult; Algorithms; Anxiety Disorders; Autoreceptors; Brain; Brain Chemistry; Citalopram; Data Interp | 2010 |
The loudness dependence of the auditory evoked potential (LDAEP) as a predictor of the response to escitalopram in patients with generalized anxiety disorder.
Topics: Adult; Aged; Anxiety Disorders; Citalopram; Electromagnetic Phenomena; Evoked Potentials, Auditory; | 2011 |
Changes in regional brain volumes in social anxiety disorder following 12 weeks of treatment with escitalopram.
Topics: Adolescent; Adult; Aged; Anxiety; Anxiety Disorders; Brain; Citalopram; Depressive Disorder; Diagnos | 2010 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Daily emotional dynamics in depressed youth: a cell phone ecological momentary assessment study.
Topics: Adolescent; Affect; Age Factors; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cell P | 2011 |
Escitalopram for psychogenic nausea and vomiting: a report of two cases.
Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; | 2011 |
[Depression and professional activity: results of the NEXTEP study].
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cohort Studies; Comb | 2011 |
Angular cheilitis after paroxetine treatment.
Topics: Adult; Anxiety Disorders; Cheilitis; Citalopram; Diagnosis, Differential; Drug Eruptions; Drug Subst | 2012 |
Reversal of SSRI-associated urinary retention with mirtazapine augmentation.
Topics: Adrenergic alpha-Antagonists; Adult; Anti-Anxiety Agents; Antidepressive Agents, Tricyclic; Anxiety | 2012 |
Cognitive therapy for anxious depression in STAR(*) D: what have we learned?
Topics: Adult; Antidepressive Agents; Anxiety Disorders; Citalopram; Cognitive Behavioral Therapy; Comorbidi | 2012 |
Therapeutic implications of adding the psychotropic drug escitalopram in the treatment of patients suffering from moderate-severe psoriasis and psychiatric comorbidity: a retrospective study.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; De | 2014 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagon | 2012 |
Depression among dialysis patients: barriers to good care.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2012 |
Information processing bias and pharmacotherapy outcome in older adults with generalized anxiety disorder.
Topics: Adult; Aged; Aging; Anxiety; Anxiety Disorders; Attention; Citalopram; Decision Making; Emotions; Fe | 2013 |
Re: citalopram versus psychological training for depression and anxiety symptoms in hemodialysis patients.
Topics: Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Depressive Disorder; Female | 2013 |
Citalopram for the treatment of adolescent anxiety disorders: a pilot study.
Topics: Adolescent; Anxiety Disorders; Citalopram; Humans; Pilot Projects; Selective Serotonin Reuptake Inhi | 2002 |
Dexamphetamine for obsessive-compulsive disorder.
Topics: Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; | 2003 |
Effects of citalopram on worry and brain activation in patients with generalized anxiety disorder.
Topics: Adult; Anti-Anxiety Agents; Anxiety Disorders; Arousal; Brain; Brain Mapping; Citalopram; Dose-Respo | 2004 |
Drugs vs. talk therapy: 3,079 readers rate their care for depression and anxiety.
Topics: Antidepressive Agents; Anxiety; Anxiety Disorders; Bupropion; Citalopram; Cyclohexanols; Depression; | 2004 |
Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
Topics: Adult; Anxiety Disorders; Brain; Citalopram; Female; Humans; Limbic System; Male; Obsessive-Compulsi | 2004 |
Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Age Factors; Antidepressive Agents; Anxiety Disorders; Citalopram; Cohort Studies | 2005 |
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study.
Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal | 2005 |
Conclusions inconsistent with results with citalopram.
Topics: Age Factors; Anxiety Disorders; Citalopram; Double-Blind Method; Drug Administration Schedule; Drug | 2005 |
Predictors of symptom resolution in panic disorder after one year of pharmacological treatment: a naturalistic study.
Topics: Adult; Agoraphobia; Anxiety Disorders; Citalopram; Diagnostic and Statistical Manual of Mental Disor | 2006 |
Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
Topics: Adolescent; Adult; Anxiety Disorders; Citalopram; Cohort Studies; Cost Sharing; Databases, Factual; | 2006 |
Detection and treatment of depressive and anxiety disorders among cancer patients: feasibility and preliminary findings from a liaison service in an oncology division.
Topics: Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents; Anxiety Disorders; Citalopram; Depressive D | 2006 |
Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.
Topics: Adult; Aged; Amino Acid Substitution; Antidepressive Agents, Second-Generation; Anxiety Disorders; B | 2006 |
Cost-effectiveness analysis of escitalopram compared with paroxetine in treatment of generalized anxiety disorder in the United Kingdom.
Topics: Anxiety Disorders; Citalopram; Cost-Benefit Analysis; Decision Support Techniques; Humans; Paroxetin | 2006 |
Escitalopram-associated hyponatremia.
Topics: Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Citalopram; Electrocardiography; F | 2007 |
Escitalopram in a working population: results from an observational study of 2378 outpatients in Austria.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Anxiety Disorders; Austria; Cital | 2007 |
Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anxiety Disorders; Citalopram; Drugs, Generic; Female; Human | 2007 |
Caffeine consumption, sleep, and affect in the natural environments of depressed youth and healthy controls.
Topics: Adolescent; Affect; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Beverages; Caf | 2008 |
Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.
Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety Disorders | 2008 |
Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder.
Topics: Adrenergic Uptake Inhibitors; Antipsychotic Agents; Anxiety Disorders; Atomoxetine Hydrochloride; At | 2007 |
Acute pregabalin reversal of citalopram-induced sexual dysfunction in generalized anxiety disorder.
Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Anxiety Disorders; | 2008 |
Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Antidepressive Agents; Anxiety Disorders; Citalopram; C | 1996 |
Serotonin syndrome. A common but often unrecognized psychiatric condition.
Topics: Aged; Anxiety Disorders; Buspirone; Citalopram; Depression; Female; Humans; Selective Serotonin Reup | 2001 |
Treatment of social anxiety disorder with citalopram.
Topics: Adult; Anxiety Disorders; Citalopram; Female; Humans; Male; Middle Aged; Selective Serotonin Reuptak | 2002 |